Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways ...
Shares of Kura Oncology rose after the company said its potential treatment for clear cell renal cell carcinoma, or ccRCC, demonstrated robust antitumor activity and a manageable safety profile in ...
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI ...
In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline ...
In this segment on advanced renal cell carcinoma, Dr. Geynisman raises the increasingly relevant question of how prior ...
Kura Oncology (KURA) stock rises as the company posts data from a Phase 1 trial for its experimental kidney cancer therapy, darlifarnib. Read more here.
Investing.com -- Kura Oncology (NASDAQ:KURA) shares rose 9% Friday following the release of preliminary trial data showing its drug combination demonstrated activity in patients with clear cell renal ...
Kura Oncology Inc. KURA shares are up during Friday’s premarket session as the company reported promising data regarding its ...
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent ...
Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells.
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results